Cost efficacy of platelet glycoprotein IIb/IIIa antagonists in clinical trials and clinical practice.
Young
John J
JJ
Carl and Edyth Lindner Center for Research and Education, Ohio Heart Health Center, Cincinnati, Ohio, USA.
Kereiakes
Dean J
DJ
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000191:economics; D003328:Coronary Thrombosis / Q000188:drug therapy / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use; D010455:Peptides / Q000191:economics / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D010818:Practice Patterns, Physicians' / Q000191:economics; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab